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Mortality Differences Between Men and
Women After Percutaneous Coronary Interventions
A 25-Year, Single-Center Experience
Mandeep Singh, MD,* Charanjit S. Rihal, MD,* Bernard J. Gersh, MB, CHB, DPHIL,*
Veronique L. Roger, MD,* Malcolm R. Bell, MD,* Ryan J. Lennon, MS,† Amir Lerman, MD,*
David R. Holmes, JR, MD*
Rochester, Minnesota
Objectives Our aim was to examine whether gender-based differences in mortality after percutaneous coronary interven-
tions (PCIs) have changed in the past 25 years.
Background Women with coronary artery disease have a higher risk of adverse outcomes after PCIs than do men. Recent
temporal trends in short-term and long-term mortality in women after PCIs are unknown.
Methods We performed a retrospective cohort study of 18,885 consecutive, unique patients who underwent PCIs between
1979 and 1995 (early group, n  7,904, 28% women) and between 1996 and 2004 (recent group, n  10,981,
31% women). Thirty-day and long-term mortality were compared by gender.
Results Compared with men, women undergoing PCIs were older and more likely to have diabetes mellitus, hyperten-
sion, or hypercholesterolemia. Overall, PCI was successful in 89% of women and 90% of men. In the recent
group, 30-day mortality was significantly reduced compared with that in the early group in women (2.9% vs.
4.4%, p  0.002) and men (2.2% vs. 2.8%, p  0.04). However, long-term survival was similar between the
early and recent groups among both men and women. After adjustment for risk factors, there was no difference
between men and women from 1994 onward for either 30-day or long-term outcomes.
Conclusions The 30-day mortality after PCI in men and women has decreased in the past 25 years. After accounting for
baseline risks, no differences in short-term or long-term mortality were observed between men and
women. (J Am Coll Cardiol 2008;51:2313–20) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.066P
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geart disease is the leading cause of death in women—
pproximately 400,000 deaths annually. In the U.S., around
0% of the approximately 1 million annual percutaneous
oronary intervention (PCI) procedures are performed in
omen. It is important, therefore, to carefully document the
utcomes of women undergoing this procedure (1).
See page 2321
Women undergoing PCI are known to have a higher
ncidence of adverse outcomes than men (2–4). However,
he results of risk-adjusted analyses of short-term and
ong-term outcomes after PCI are discordant with earlier
tudies demonstrating an adverse prognosis in women (2,3);
ore recent data indicate narrowing of the gender gap (5,6).
rom the *Division of Cardiovascular Diseases and the †Division of Biostatistics,
ayo Clinic, Rochester, Minnesota.t
Manuscript received July 6, 2007; revised manuscript received January 2, 2008,
ccepted January 14, 2008.rior studies have shown that women undergo PCI later in
he course of disease, have more comorbid conditions, and
ave more technically challenging coronary anatomy (7–9).
Most studies reporting on the gender-based differences in
utcomes after PCI date from the early to mid-1990s.
oronary interventional practice since 1995 has been revo-
utionized with stents, combination oral antiplatelet ther-
py, glycoprotein IIb/IIIa inhibitors, and, even more re-
ently, drug-eluting stents. To address the hypothesis that
he gender gap in outcomes after PCI has narrowed, we
erformed an analysis of the Mayo Clinic PCI registry data:
) to characterize the current (1996 to 2004) practice and
utcomes of PCI in women; 2) to compare current practice
ith past (1979 to 1995) practice; and 3) to compare the
xperience of women and men.
ethods
atient population. Since 1979, data from patients under-
oing PCI at Mayo Clinic have been recorded in a prospec-
ive registry. For the present study, we considered 19,238
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Mortality After PCI in Women Versus Men June 17, 2008:2313–20consecutive, unique patients un-
dergoing PCI at Mayo Clinic
Rochester. We considered the
first PCI performed at Mayo
Clinic for each patient; thus, pa-
tients with prior PCI performed
elsewhere were included, and re-
peat procedures performed at
Mayo Clinic were excluded. A
total of 353 patients did not al-
ow research use of their medical records and were excluded
s required by State of Minnesota statute. The resulting
ohort of 18,885 patients was divided into 2 groups for
nalysis: those treated in 1979 through 1995 (“early” group;
,904 patients, 28% women) and those treated in 1996
hrough 2004 (“recent” group; 10,981 patients, 31%
omen). The cutoff point of 1996 was chosen because
ubstantial changes in the treatment of and pharmacother-
py for coronary artery disease (e.g., routine use of dual oral
ntiplatelet therapy and stents) occurred around that time
eriod. The Mayo Clinic Institutional Review Board ap-
roved the study.
The medical records of all patients were reviewed to
etermine post-procedural outcomes. Procedural success
as defined as decrease in the diameter of stenosis to less
han 50%, without death, Q-wave myocardial infarction, or
oronary artery bypass grafting surgery. All in-hospital
eaths during the index hospital stay were attributed to the
rocedure. Additional data were recorded regarding non-
ardiac comorbid conditions such as cerebrovascular disease,
eripheral vascular disease, malignancy, renal disease, dia-
etes mellitus, and hypertension.
ollow-up. Follow-up information for all patients dis-
issed from the hospital was obtained by an experienced
ata technician by telephone 6 and 12 months after the
nitial procedure and annually thereafter. Information re-
arding vital status was sought. In the event of death, a
atient’s next of kin reported the patient’s health status
receding the event, and the death certificate was requested.
ayo Clinic records were reviewed for all patients who were
ollowed up at this institution, and verification of events
ccurring at other hospitals was obtained from the attending
hysicians. Routine review and editing of out-of-range data
ere performed to ensure quality of data received after
ismissal from the hospital.
tatistical analysis. Continuous data were summarized as
ean  standard deviation; discrete data were summarized
s frequencies and group percentages. Linear and logistic
egression models were used to test whether gender differ-
nces varied between the early and recent groups (i.e., test
or interaction). Comparisons between men and women
ithin era or between eras within gender are not reported;
ost of these comparisons were significant because of the
arge sample size. Values of p  0.05 were considered
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
PCI  percutaneous
coronary interventionignificant. lThe 2 end points of interest were 30-day and long-term
ortality rates. Although patients were scheduled for
-month and yearly telephone contact, some patients were
ot contacted after discharge; thus, neither 30-day nor
ong-term follow-up data were available. Therefore, 30-day
nd long-term mortality rates were analyzed with Kaplan-
eier estimates and Cox proportional hazards models. The
ormal analyses were based on long-term mortality; all
azard ratios, effects estimates, and p values are based on
hese outcomes. The 1-year estimates are provided for
escriptive purposes. For actual event rates, we reported
-year rates for the absolute risks (e.g., Kaplan-Meier
stimate) versus relative risks (e.g., hazard ratio).
Multivariate Cox regression models were used to estimate
artial hazard ratios. Because data regarding some impor-
ant risk factors (pre-procedural shock, peripheral vascular
isease, renal disease, history of cerebrovascular accident/
ransient ischemic attack, American College of Cardiology/
merican Heart Association [ACC/AHA] lesion classifi-
ation, bifurcated lesion, tumor/lymphoma/leukemia, and
etastatic cancer) were not recorded in the database until
ate 1993, the multivariate analysis was restricted to 1994
nward. All but 2 covariates had6% missing data. History
f high cholesterol was missing in 11% of patients, and
CC/AHA lesion type was missing in 9%. Multiple impu-
ation was used to impute replacement values in 5 imputa-
ion data sets; models were then estimated for each data set.
issing data were imputed using the aregImpute function
n the Hmisc library for S-Plus (Insightful Corp., Seattle,
ashington). The SAS 9.1 procedure PROC MIANA-
YZE (SAS Institute, Cary, North Carolina) was used to
ombine each imputation’s parameter estimates (10,11).
Because the outcomes trends over time are unlikely to
e strictly linear, we used restricted cubic splines to
odel curvilinear associations between procedure date
nd the outcome of interest, as well as other continuous
ovariates. In general, splines are piecewise equations tied
ogether at locations called knots. Splines are similar to
olynomial equations but are able to fit a more diverse set
f relationships. We used 5 knots for the splines for
rocedure date and included an interaction between
ender and date. Thus, 9 parameters were estimated to
escribe the post-PCI mortality trends over time for men
nd women.
esults
he baseline clinical characteristics for the study population
re shown in Table 1. In both time periods, women were
lder and had more severe symptoms of coronary heart
isease, more heart failure, and more frequent presentation
ith acute coronary syndromes (unstable angina, Canadian
ardiovascular Society angina class III and IV) than men.
omen also had a higher prevalence of comorbid condi-
ions including diabetes mellitus and hypertension but were
ess likely to have had prior surgical or percutaneous
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June 17, 2008:2313–20 Mortality After PCI in Women Versus Menoronary revascularization procedures. Table 2 summarizes
he angiographic characteristics and highlights the number
f patients discharged on evidence-based medications. In-
reased use of evidence-based medications for secondary
revention was noted in the recent group. The mean
aseline Characteristics of the Early and Recent Groups*
Table 1 Baseline Characteristics of the Early and Recent Group
Variable
Early Group (1979 to 1995
Women (n  2,203) Men (n 
Age, yrs, mean  SD 67.3 11.1 62.4
MI, day of PCI or 24 h 280 (13) 821
MI, 1 to 7 days before PCI 395 (18) 838
Pre-procedural shock 55 (5) (n  1,022)‡ 77 (3) (n
Unstable angina 1,633 (74) 3,898
CCS class III or IV 1,581 (72) 3,483
Diabetes mellitus 514 (23) 846
Hypertension 1,316 (60) 2,512
Body mass index, kg/m2, mean  SD 27.7 5.6 28.0
History of cholesterol 240 mg/dl 978 (54) (n  1,801)‡ 1,931 (41) (n
CHF on presentation 224 (10) 349
History of CHF 330 (15) 537
Current smoker 422 (19) 1,281
Prior MI 1,200 (54) 3,228
Prior PTCA 60 (3) 146
Prior CABG 274 (12) 1,058
Peripheral vascular disease 65 (12) (n  541)‡ 160 (12) (n
CVA/TIA 58 (11) (n  543)‡ 116 (9) (n
Moderate/severe renal disease 23 (4) (n  544)‡ 54 (4) (n
Values are number of patients (%) unless otherwise stated; †tests for a change in the difference
CABG coronary artery bypass grafting surgery; CCS Canadian Cardiovascular Society; CHF
nfarction; PCI  percutaneous coronary intervention; PTCA  percutaneous transluminal coronar
edications, Procedural Data, and Lesion Characteristics*
Table 2 Medications, Procedural Data, and Lesion Characterist
Variable
Early Group (1979 to 1995)
Women (n  2,203) Men (n 
Medications at discharge
Antiplatelet therapy 1,767 (83) (n  2,125) 4,724 (85) (n
Beta-blockers 993 (45) 2,655 (4
Lipid-lowering drugs 250 (11) 613 (1
ACE inhibitors 237 (11) 469 (8
Medication score 3 or 4 240 (11) 566 (1
Glycoprotein IIb/IIIa antagonists 4 (0.2) 13 (0
Stent use 186 (8) 555 (1
Multivessel disease 1,067 (48) 2,815 (4
ACC/AHA type C lesions 279 (29) (n  961) 838 (35) (n
Maximum device size used, mm 3.1 0.9 3.2
Percentage stenosis, mean  SD
Pre-procedure 90.2 8.1 89.9
Post-procedure 32.5 21.4 32.7
Lesion characteristics
Calcified 590 (28) (n  2,083) 1,389 (26) (n
Bifurcation 58 (11) (n  530) 141 (11) (n
Thrombus 789 (40) (n  1,993) 2,120 (41) (n
Ostial 163 (17) (n  981) 383 (16) (n
EF 40% 111 (5) 335 (6Values are number of patients (%) unless otherwise stated; †tests for a change in the difference betwe
ACC/AHA  American College of Cardiology/American Heart Association; ACE  angiotensin-convertinedication score (based on the number of evidence-based
edications, such as antiplatelet therapy, beta-blockers,
ngiotensin-converting enzyme inhibitors, and lipid-
owering agents, the patient is receiving at dismissal) was
igher in the recent group and comparable in men and
Recent Group (1996 to 2004)
Interaction
p Value†1) Women (n  3,365) Men (n  7,616)
69.4 12.0 64.7 11.8 0.48
625 (19) 1,380 (18) 0.07
571 (17) 1,156 (15) 0.23
9)‡ 170 (5) 301 (4) 0.10
1,977 (59) 4,250 (56) 0.02
1,800 (53) 3,611 (47) 0.001
935 (28) 1,634 (22) 0.007
2,453 (73) 4,571 (60) 0.46
29.3 6.4 29.4 5.1 0.18
37)‡ 2,312 (77) (n  3,018)‡ 4,824 (71) (n  6,829)‡ 0.002
444 (13) 686 (9) 0.27
572 (17) 940 (12) 0.16
589 (18) 1,489 (20) 0.34
1,747 (52) 3,950 (52) 0.23
338 (10) 968 (13) 0.06
448 (13) 1,570 (21) 0.57
29)‡ 355 (11) 762 (10) 0.67
2)‡ 409 (12) 765 (10) 0.99
6)‡ 123 (4) 273 (4) 0.93
en men and women from the early to the recent group; ‡number with data available.
tive heart failure; CVA/TIA cerebrovascular accident/transient ischemic attack; MImyocardial
plasty.
Recent Group (1996 to 2004)
Interaction
p Value†) Women (n  3,365) Men (n  7,616)
69) 3,102 (99) (n  3,130) 7,207 (99) (n  7,252) 0.34
2,525 (75) 5,666 (74) 0.19
2,203 (65) 5,136 (67) 0.11
1,507 (45) 3,200 (42) 0.045
2,174 (65) 4,968 (65) 0.16
1,642 (49) 4,069 (53) 0.94
2,908 (86) 6,673 (88) 0.64
1,546 (46) 3,758 (49) 0.09
94) 1,270 (42) (n  3,056) 3,130 (45) (n  6,885) 0.22
3.3 0.6 3.4 0.7 0.51
87.1 9.7 87.8 9.4 0.002
8.6 17.6 8.8 18.0 0.98
51) 1,222 (40) (n  3,026) 2,702 (39) (n  6,864) 0.29
01) 406 (13) (n  3,185) 923 (13) (n  7,177) 0.91
22) 984 (31) (n  3,164) 2,471 (35) (n  7,131) 0.22
30) 512 (21) (n  2,458) 1,206 (21) (n  5,712) 0.50
335 (10) 870 (11) 0.95s*
)
5,70
11.2
(14)
(15)
 2,53
(68)
(61)
(15)
(44)
4.3
 4,7
(6)
(9)
(23)
(57)
(3)
(19)
 1,3
 1,33
 1,33
betweics*
5,701
 5,5
7)
1)
)
0)
.2)
0)
9)
 2,3
0.9
8.7
21.0
 5,3
 1,3
 5,1
 2,4
)en men and women from the early to the recent group.
g enzyme; EF  ejection fraction.
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Mortality After PCI in Women Versus Men June 17, 2008:2313–20omen (12). The use of stents and glycoprotein IIb/IIIa
eceptor inhibitors also was similar. Despite the greater
everity of symptoms of angina, women had lower preva-
ence of multivessel disease, thrombus, and ACC/AHA
ype C lesions, and fewer women than men had left
entricular ejection fractions 40%.
Table 3 shows the procedural success rate and in-hospital,
0-day, and 1-year outcomes. Procedural success was high
nd similar for the 2 genders (women, 89%; men, 90%),
ith improvements noted in the recent time period. A total
f 522 deaths occurred in the first 30 days, starting from the
ate of PCI. The 30-day mortality for women and men
4.4% and 2.8%, respectively) in the early group was
ignificantly higher than that of women and men in the
ecent group (2.9% and 2.2%; p  0.001). In addition,
0-day mortality in the recent group was significantly
ecreased compared with the early group in women (p 
.002) and men (p  0.04).
nadjusted survival. Follow-up was available through
eptember 2005, with annual follow-up complete in 92% of
atients. Median duration of follow-up was 13.2 years
interquartile range 11.0 to 17.0 years) for the early group
nd 4.1 years (interquartile range 2.0 to 6.2 years) for the
ecent group. There were 4,791 deaths during the long-term
ollow-up period (after a median of 7.0 years), 658 of which
ccurred in the first year after PCI. Figure 1 shows the
verall estimated survival rates for women and men.
omen had slightly lower survival than men, and for both
enders, especially men, survival was similar between the 2
ime periods. The probability of survival at 5 years was 79%
nd 81% in women versus 83% and 83% in men, in the early
nd recent groups, respectively.
emporal trends for 30-day and long-term mortality. We
urther analyzed whether differences in 30-day and long-
erm mortality rates have significantly changed over time
rocedural Success and Outcomes After PCI*
Table 3 Procedural Success and Outcomes After PCI*
Variable
Early Group (1979 to 1995)
Women (n  2,203) Men (n  5,
Procedural success 1,821 (82.7) 4,806 (84.
In-hospital events
Death 89 (4.0) 145 (2.5
Q-wave MI 23 (1.0) 67 (1.2
Stroke 5 (0.2) 3 (0.1
Emergent CABG 69 (3.1) 172 (3.0
30-day events‡
Death 97 (4) 160 (3)
Any MI 16 (1) 32 (1)
1-yr events‡
Death 88 (4) 194 (4)
Any MI 106 (5) 226 (4)
Repeat revascularization 361 (17) 1,015 (19)
Values are number of patients (%); †tests for a change in the difference between men and wome
stimator.
Abbreviations as in Table 1.nd whether the gender differential has varied over time. Tovoid overfitting, we estimated 35 parameters for the 30-day
odel and 40 parameters for the long-term model. Analyses
f long-term mortality started from day 31. For long-term
ortality, we excluded patients who had less than 30 days of
ollow-up due to death (n  522) or censoring (n  249)
total n  771; 4%). Figures 2 and 3 show unadjusted
stimates for 30-day and 1-year mortality rates based on the
ear of PCI. Women had significantly higher event rates at
0 days (p  0.001) and over long-term follow-up (p 
.001). Tests for interaction were nonsignificant (p  0.23,
0 days; and p  0.49, long term), indicating that the
ifference in men’s and women’s mortality rates was similar
ver time.
To discern whether better application of drug treatment
nfluenced improvement in mortality in women, we tested
re-dismissal percentage utilization of 6 medications (beta-
lockers, aspirin, lipid-lowering agents, calcium-channel
Recent Group (1996 to 2004)
Interaction
p Value†Women (n  3,365) Men (n  7,616)
3,142 (93.4) 7,153 (93.9) 0.80
83 (2.5) 139 (1.8) 0.38
48 (1.4) 87 (1.1) 0.44
30 (0.9) 35 (0.5) 0.29
28 (0.8) 60 (0.8) 0.95
96 (3) 169 (2) 0.25
14 (0) 34 (0) 0.43
120 (4) 256 (4) 0.49
109 (3) 236 (3) 0.31
352 (11) 767 (11) 0.20
the early to the recent group; ‡percentages are based on the event rates from the Kaplan-Meier
Figure 1 Kaplan-Meier Curves Estimating Overall Survival
Estimated survival is shown in men and women stratified by
time period: early group (1979 to 1995) and recent group (1996 to 2004).701)
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June 17, 2008:2313–20 Mortality After PCI in Women Versus Menlockers, angiotensin-converting enzyme inhibitors, and
iuretics) and its interaction with gender to influence
ong-term mortality. The results indicated that medication
se was not more effective in women (data not shown).
After adjusting for risk factors, the mortality rates were
ot significantly different between men and women at 30
ays (p  0.10) (Fig. 4) and over long-term follow-up (p 
.42) (Fig. 5). Test for interaction was nonsignificant at 30
ays and long term (p  0.06 and p  0.84, respectively).
he estimates from the multiple regression models and the
isk factors used for adjustment are shown in Table 4.
omplete case analysis. We also analyzed the outcomes
ased only on the patients without any missing data.
omplete data were available for only 9,392 of 12,798
ubjects for the 30-day mortality model. For long-term
ortality, only 7,598 of 12,324 observations had complete
ata. The analysis of 30-day mortality in this subset indi-
ates no significant difference between men and women
p  0.18) and no significant interaction in time trends
Figure 2 Unadjusted 30-Day Mortality Rates
Mortality is shown in men and women by
year of percutaneous coronary intervention (PCI).
Figure 3 Unadjusted 1-Year Mortality Rates
Mortality is shown in men and women by
year of percutaneous coronary intervention (PCI).p  0.11) between men and women. The estimated
robabilities from this model are similar to those from the
mputed data model, although they show a slightly de-
reased mortality risk over time. The long-term mortality
nalysis of the subset shows no significant difference be-
ween men and women (p  0.43), with results similar to
he multiple imputation analysis.
iscussion
ver the past 25 years, the outcomes of PCI in women have
mproved, as is the case in men. Nonetheless, risk profile
nd absolute adverse event rates in women are higher than
n men, and this has not changed over time, as shown in this
nd prior studies from our institution (13,14). After adjust-
ent for risk factors, the 30-day and long-term mortality
ates are similar in men and women. Additionally, the time
rends in the past 25 years fail to show any gender-related
isparity in the improved outcomes after PCI that have been
oted over time.
Figure 4 Adjusted 30-Day Mortality Rates
Mortality is shown in men and women by year of percutaneous
coronary intervention (PCI) after adjustment for factors listed in Table 4.
Figure 5 Adjusted 1-Year Mortality Rates
Mortality is shown in men and women by year of percutaneous
coronary intervention (PCI) after adjustment for factors listed in Table 4.
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Mortality After PCI in Women Versus Men June 17, 2008:2313–20Earlier studies evaluating gender differences in outcomes
f PCI showed disparate results but in general reported
igher complication rates in women (2,3). The earlier
ational Heart, Lung, and Blood Institute PCI registry
ndicated female gender to be independently predictive of
n-hospital mortality (2). The adverse outcomes in women
ere attributed largely to older age, lower body surface area,
maller size of coronary arteries, higher risk profile, and
ore prevalent comorbid conditions. More recent studies,
owever, more consistently show improvement in rates of
n-hospital complications after PCI in women that matched
Multivariate Predictors of 30-Day and Long-Term
Table 4 Multivariate Predictors of 30-Day a
Variable
30-Day O
HR (95% CI)
Time and gender† 9 df
Gender effect 5 df
Interaction‡ 4 df
Nonlinearity§ 6 df
Age 3 df spline
Emergency PCI 2.36 (1.64–3.39)
Elective PCI 0.65 (0.43–0.98)
Pre-PCI shock 5.03 (3.81–6.63)
MI
0–6 h 1.59 (1.05–2.40)
6–23 h 1.32 (0.85–2.06)
24 h
1–7 days 1.64 (1.17–2.31)
7 days 1.26 (0.95–1.66)
CHF on presentation 1.75 (1.34–2.29)
History of CHF
Hyperlipidemia
Body mass index 2 df spline
Renal disease 2.18 (1.55–3.07)
Current smoking
History of smoking 1.10 (0.85–1.41)
History of CVA/TIA
Diabetes mellitus 1.19 (0.91–1.54)
Hypertension 1.11 (0.84–1.45)
B2/C lesion
Type C lesion 1.49 (1.07–2.08)
2-vessel disease (70%) 1.24 (0.92–1.66)
3-vessel disease (70%) 1.95 (1.42–2.68)
Prior CABG 1.02 (0.76–1.39)
Previous PCI 1.31 (0.90–1.91)
PVD 1.65 (1.24–2.19)
PCI on a severe bend
Thrombus in any lesion
Metastatic cancer
Tumor/leukemia/lymphoma
Tumor/metastatic cancer 1.08 (0.80–1.45)
*Splines were fitted to allow for nonlinear relationships between contin
together at locations called knots. Splines are similar to polynomial equati
see the Statistical Analysis section; †four parameters were estimated tom
trends over time in men, and 1 parameter was estimated to allow for a d
gender is tested by comparing the fullmodel to amodelwith only a single t
in outcomes between men and women has been the same over time; §t
CHF  congestive heart failure; CI  confidence interval; df  degr
Table 1.he rates in men. Jacobs et al. (5) concluded, from National eeart, Lung, and Blood Institute data from 1993 to 1994,
hat gender differences decreased and women had signifi-
antly improved outcomes after PCI. The improvement for
omen has been reported not only in elective PCI but also
n acute coronary syndrome, including acute myocardial
nfarction and shock (15,16). Malenka et al. (17) made
imilar observations, reporting no gender differences in the
utcomes from 1994 to 1999 in 33,666 consecutive hospital
dmissions for PCI in northern New England. Although
ost studies compiled in the AHA statement (6) indicate
hat more recent data do not support gender-based differ-
come*
ng-Term Outcome*
e Long-Term Outcome
p Value HR (95% CI) p Value
0.007 9 df 0.02
0.10 5 df 0.42
0.06 4 df 0.84
0.01 6 df 0.17
0.001 3 df spline 0.001
0.001 1.15 (0.99–1.33) 0.06
0.04 0.91 (0.84–1.00) 0.053
0.001
0.03
0.22
0.99 (0.84–1.17) 0.88
0.004 1.05 (0.94–1.18) 0.36
0.10 1.21 (1.08–1.36) 0.001
0.001
2.31 (2.11–2.53) 0.001
0.74 (0.67–0.82) 0.001
0.29 2 df spline 0.001
0.001 2.28 (1.96–2.65) 0.001
1.31 (1.15–1.48) 0.001
0.47 1.23 (1.12–1.34) 0.001
1.36 (1.23–1.51) 0.001
0.20 1.68 (1.54–1.83) 0.001
0.47 1.09 (0.99–1.19) 0.08
1.15 (1.01–1.31) 0.03
0.02 1.10 (1.01–1.21) 0.04
0.16 1.18 (1.08–1.29) 0.001
0.001 1.26 (1.14–1.40) 0.001
0.88 1.55 (1.41–1.70) 0.001
0.16 1.02 (0.90–1.16) 0.72
0.001 1.50 (1.35–1.66) 0.001
1.08 (0.93–1.26) 0.32
0.89 (0.81–0.98) 0.02
3.15 (2.39–4.14) 0.001
1.41 (1.28–1.57) 0.001
0.63
riables and the hazard ratio (HR). Splines are piecewise equations tied
are able to fit amore diverse set of relationships. For further information,
e trends over time in women, 4 parameters were estimated tomodel the
intercept between men and women. The interaction between time and
d for bothmenandwomen; ‡tests the null hypothesis that the difference
null hypothesis that the trend over time is strictly linear.
eedom; PVD  peripheral vascular disease; other abbreviations as inOut
nd Lo
utcom
uous va
ons but
odel th
ifferent
ime tren
ests thences in the in-hospital outcome after PCI, the early hazard
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June 17, 2008:2313–20 Mortality After PCI in Women Versus Menarried by women undergoing coronary stenting was noted
n a study from 2000 (18). We believe that the reasons for
emporal improvement noted in both genders are most
ikely multifactorial. The possible determinants of mortality
eduction over time include newer technologies, improved
perator experience, and better education and adherence to
vidence-based medications by the patients.
Few reports have examined long-term gender-based dif-
erences related to PCI. Similar to our observations, the
ecent National Heart, Lung, and Blood Institute registry
tudy noted higher unadjusted 1-year mortality in women
han men (6.5% vs. 4.3%; p  0.02). However, after
djustment for other variables, gender was not a predictor of
eath or death and/or myocardial infarction. The present
nalysis is unique in that it spans 25 years and provides not
nly temporal trends in outcome between the genders but
lso a long framework to analyze any gender differences over
ime. The present analysis shows significant improvement
ver time in outcome after PCI in both genders and is
onsonant with recent observations from other centers in
oting no differences in the outcome between the genders
fter adjustment for other variables (16). The higher in-
ospital mortality noted in women is likely multifactorial
nd may be largely due to increased risk profile (advanced
ge at PCI, more frequent presentation with acute coronary
yndrome, and higher prevalence of comorbid conditions),
ecause the gender differences for in-hospital complications
arrowed or disappeared after adjustment for these and
ther significant risk factors predicting outcome.
The long-term predictors associated with lower mortality
ncluded hyperlipidemia and presence of thrombus. We
ave shown previously that hyperlipidemia was associated
ith decreased in-hospital mortality and increased post-
rocedural cardiac biomarker levels (19). The decreases in
dverse outcomes were limited to patients taking statin
rugs at the time of PCI. However, the 1-year survival
n successful PCI was similar. Other studies have shown
mproved survival for patients receiving statin therapy after
CI (20,21). Most studies support angiographic thrombus
s a predictor of in-hospital mortality but not of long-term
ortality. In the 2 studies from our group regarding
hrombus, mortality at 6 months to 1 year was similar in
roups with and without thrombus (22,23). Thrombus,
owever, was associated with higher rates of in-hospital and
-month myocardial infarction. The survival advantage in
atients with thrombus is intriguing, and the reasons for it
re, at best, speculative. We measured only mortality and
ot other end points such as myocardial infarction associ-
ted with thrombus. Favorable selection of survivors of PCI
ould be another reason for lower mortality in this sub-
roup.
Our study showed high and similar rates of evidence-
ased medications (given at the time of discharge) in both
enders in the recent group—66% discharged with a med-
cation score of 3 or 4. Such high medication scores were
ssociated with lower rates of death or myocardial infarction rn follow-up after PCI in a recent study from our institution
12). We also noted similar utilization of stents and glyco-
rotein IIb/IIIa receptor inhibitors in both genders in the
ecent group. The results from our study at a tertiary care,
igh-volume center are incongruent with most available
rials and multicenter quality improvement registries report-
ng underutilization of evidence-based medications, coro-
ary angiography, and revascularization procedures in
omen (24–26). Such disparities highlight underutilization
f evidence-based therapies in women in the real world
ersus the results obtained at a single-center, tertiary care,
eferral hospital. We did not examine the utilization rates of
nvasive procedures in our dataset or adherence to evidence-
ased medications by the patients who did not undergo
oronary angioplasty. Clearly, after coronary revasculariza-
ion was performed, the early and long-term outcomes in
oth genders were similar, underscoring the need to increase
wareness among patients and physicians that outcome after
CI will likely be similar in men and women. Efforts should
e taken to streamline, implement, and improve adherence
o evidence-based medications and increase and optimize
he utilization of invasive procedures in appropriate high-
isk patients regardless of gender (14,26–28).
tudy limitations. This study is a retrospective analysis
rom a single, large-volume, tertiary care center, which
imits its generalizability. For some variables, the percentage
f missing data was high, especially for earlier time periods,
hich restricted our ability to adjust for risk factors for PCI
efore 1994. We used multiple imputation to allow analysis
f all observations from 1994 onward, while accounting for
he uncertainty of unmeasured variables. We did not report
ther major adverse cardiovascular outcomes, including
yocardial infarction, because the definitions of outcomes
ave changed over time. We could not elaborate on the
hysician and patient factors influencing the decision to
erform coronary angiography and PCI. Even as we limited
ur analysis to short-term and long-term mortality, it is
lausible that different methods of follow-up for patients
reated at or outside our institution could have led to some
isclassification bias.
onclusions
he results of the present study indicate that after PCI,
0-day and long-term mortality in both genders has de-
reased in the past 25 years. The higher short-term and
ong-term mortality in women are related more to under-
ying risk factors and comorbid conditions. After adjust-
ent for such factors, survival is comparable in both
enders.
cknowledgments
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